On May 28, 2020, Karyopharm presented positive data from their BOSTON study at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. Their findings are very encouraging for myeloma patients who have had one to three previous lines of therapy, and represent an important step forward in improving overall outcomes and quality of life.

Background
The BOSTON study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly XPOVIO (selinexor) in combination with once-weekly Velcade^® (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade plus low-dose dexamethasone (Vd) in adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

Originating off the heels of the successful Phase II STOMP trial, led by Dr Nizar Bahlis of Calgary, Alberta, the BOSTON study enrolled 402 patients and was conducted at over 150 clinical sites internationally. This trial was also led by Dr Bahlis yet originally, was not extended to Canadian patients. In 2017, Aldo Del Col, the late Co-founder of Myeloma Canada, heard of this promising trial and made it his mission to forge a strong relationship with Karyopharm and to push for Canadian inclusion. Through his advocacy, passion and drive, Aldo played a pivotal role in bringing the BOSTON trial to Canada: the first Canadian patient received this regimen on June 6, 2017.

Findings
The study showed a significant increase in median progression-free survival (PFS) in myeloma patients, better outcomes and overall response, as well as lower rates and less severe peripheral neuropathy than with the Vd regimen.

To see the Karyopharm press release, click here.

To see the original Myeloma Canada BOSTON Study announcement, click here.